DV
Dividend Vision

VKTX — Viking Therapeutics Inc.

Viking Therapeutics Inc. (VKTX)

Total return is 270.4% over the past 11.3 years, 74.0 points behind SPY at 344.4%. Its deepest 1-year drawdown was 45.1%.

Viking Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders, with lead candidates including VK2809 (in Phase IIb trials for non-alcoholic fatty liver disease), VK5211 (in Phase II for hip fracture recovery), VK2735 (in Phase I for metabolic disorders), and several other compounds in clinical development. The company does not currently distribute dividends. This security appeals primarily to investors with a high risk tolerance seeking exposure to early-stage biotech development, as the company has not yet commercialized any approved drugs.

VKTX key facts

Asset type
Stock
Asset class
Equity
Inception date
04/29/2015
Distribution frequency
None
Last close
$33.19
Market cap
$3,871,710,720
Average volume
1178200.0
Beta
0.685
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.67